A phase i trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Qian, Zhengzi ^a   Wang, Xianhuo ^a   Song, Zheng ^a   Zhang, Huilai ^a   Zhou, Shiyong ^a   Zhao, Jing ^a   Wang, Huaqing ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIPOSOME; URSOLIC ACID; ANTINEOPLASTIC AGENT; TRITERPENE;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CHINA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCORTICOGRAPHY; ELIMINATION HALF-LIFE; FEMALE; FEVER; GALLBLADDER CARCINOMA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATURIA; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROTEINURIA; PRURITUS; RECOMMENDED DRUG DOSE; SOLID TUMOR; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MORTALITY; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TRITERPENES;

EID: 84926512806     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/809714     Document Type: Article

References (22)

1. J. Liu, "Oleanolic acid and ursolic acid: research perspectives," Journal of Ethnopharmacology, Vol. 100, no. 1-2, pp. 92-94, 2005.
2. S. B. Mahato, S. K. Sarkar, and G. Poddar, "Triterpenoid saponins," Phytochemistry, Vol. 27, no. 10, pp. 3037-3067, 1988.
3. Y. L. Hsu, P. L. Kuo, and C. C. Lin, "Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells," Life Sciences, Vol. 75, no. 19, pp. 2303-2316, 2004.
4. S. Prasad, V. R. Yadav, R. Kannappan, and B. B. Aggarwal, "Ursolic acid, a pentacyclin triterpene, potentiates trail-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK," The Journal of Biological Chemistry, Vol. 286, no. 7, pp. 5546-5557, 2011.
5. Y. H. Choi, J. H. Baek, M. A. Yoo, H. Y. Chung, N. D. Kim, and K. W. Kim, "Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells," International Journal of Oncology, Vol. 17, no. 3, pp. 565-571, 2000.
6. H. Y. Lee, H. Y. Chung, K. H. Kim, J. J. Lee, and K. W. Kim, "Induction of differentiation in the cultured F9 teratocarcinoma stem cells by triterpene acids," Journal of Cancer Research and Clinical Oncology, Vol. 120, no. 9, pp. 513-518, 1994.
7. T. Zhang, Y. M. He, J. S. Wang, J. Shen, Y. Y. Xing, and T. Xi, "Ursolic acid induces HL60 monocytic differentiation and upregulates C/EBPβ expression by ERK pathway activation," Anti-Cancer Drugs, Vol. 22, no. 2, pp. 158-165, 2011.
8. H. J. Cha, S. K. Bae, H. Y. Lee et al., "Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells," Cancer Research, Vol. 56, no. 10, pp. 2281-2284, 1996.
9. K.-H. Sohn, H.-Y. Lee, H.-Y. Chung, H.-S. Young, S.-Y. Yi, and K.-W. Kim, "Anti-angiogenic activity of triterpene acids," Cancer Letters, Vol. 94, no. 2, pp. 213-218, 1995.
10. M. S. Kiran, R. I. Viji, V. B. Sameer Kumar, and P. R. Sudhakaran, "Modulation of angiogenic factors by ursolic acid," Biochemical and Biophysical Research Communications, Vol. 371, no. 3, pp. 556-560, 2008.
11. C. Cárdenas, A. R. Quesada, and M. Á. Medina, "Effects of ursolic acid on different steps of the angiogenic process," Biochemical and Biophysical Research Communications, Vol. 320, no. 2, pp. 402-408, 2004.
12. D. da Silva Ferreira, V. R. Esperandim, M. P. A. Toldo, J. Saraiva, W. R. Cunha, and S. de Albuquerque, "Trypanocidal activity and acute toxicity assessment of triterpene acids," Parasitology Research, Vol. 106, no. 4, pp. 985-989, 2010.
13. D. Papahadjopoulos, T. M. Allen, A. Gabizon et al., "Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy," Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, no. 24, pp. 11460-11464, 1991.
14. D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos, "Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors," Pharmacological Reviews, Vol. 51, no. 4, pp. 691-743, 1999.
15. W. W. Zou, W. T. Sun, N. Zhang, and W. F. Xu, "Enhanced oral bioavailability and absorption mechanism study of N3-O-toluyl-fluorouracil-loaded liposomes," Journal of Biomedical Nanotechnology, Vol. 4, no. 1, pp. 90-98, 2008.
16. X.-H. Wang, S.-Y. Zhou, Z.-Z. Qian et al., "Evaluation of toxicity and single-dose pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and patients with advanced solid tumors," Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, no. 2, pp. 117-125, 2013.
17. Y. Xia, G. Wei, D. Si, and C. Liu, "Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 879, no. 2, pp. 219-224, 2011.
18. A. K. Pathak, M. Bhutani, A. S. Nair et al., "Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells," Molecular Cancer Research, Vol. 5, no. 9, pp. 943-955, 2007.
19. P.-O. Harmand, R. Duval, C. Delage, and A. Simon, "Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells," International Journal of Cancer, Vol. 114, no. 1, pp. 1-11, 2005.
20. N. Gao, S. Cheng, A. Budhraja et al., "Ursolic acid induces apoptosis in human leukaemia cells and exhibits anti-leukaemic activity in nude mice through the PKB pathway," British Journal of Pharmacology, Vol. 165, no. 6, pp. 1813-1826, 2012.
21. Y. Li, D. Xing, Q. Chen, and W. R. Chen, "Enhancement of chemotherapeutic agent-induced apoptosis by inhibition of NF-κB using ursolic acid," International Journal of Cancer, Vol. 127, no. 2, pp. 462-473, 2010.
22. Q. Liao, W. Yang, Y. Jia, X. Chen, Q. Gao, and K. Bi, "LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional Chinese medicinal preparation Lu-Ying extract," Yakugaku Zasshi, Vol. 125, no. 6, pp. 509-515, 2005.